• Radiologic Technology News

NRC Approves Isotope Production Facility

Mar 03, 2016

The U.S. Nuclear Regulatory Commission has authorized a construction permit to build a facility that will produce molybdenum-99, an isotope used to make radiopharmaceuticals for use in nuclear medicine imaging. The United States has not commercially produced the substance since 1989, according to a news release from the NRC.

Mo-99 is a radioisotope that decays into the diagnostic imaging agent technetium-99m. The marker is used in millions of medical imaging procedures each year, primarily in stress tests to diagnose heart disease and bone scans to stage cancer.

SHINE Medical Technology will build the facility in Janesville, Wisconsin. “We’ve developed a greener, safer and cheaper way to produce these life-saving isotopes on a global scale,” said Greg Piefer, SHINE CEO, in a news release. “Once operational we expect the Janesville facility will improve the lives of over 1 billion people over its lifetime.” The facility is expected to use a new technique that creates the Mo-99 isotope without the use of a nuclear reactor or highly enriched uranium.

To comment on this article, please log in above with your ASRT member account. See commenting guidelines.

Leave a comment

    Leave a comment

      Your comments:
      Subject to approval
    1. Comment cannot be empty